[
    {
        "other_ids": [],
        "amendment_date": null,
        "keywords": null,
        "dcp_id": null,
        "interventional_model": "Single Group",
        "lead_org": "Kite, A Gilead Company",
        "eligibility": {
            "unstructured": [
                {
                    "inclusion_indicator": true,
                    "display_order": 0,
                    "description": "Age \u2265 18 years"
                },
                {
                    "inclusion_indicator": true,
                    "display_order": 1,
                    "description": "Advanced cancer defined as relapsed or refractory disease after a systemic standard of care treatment regimen and, if available, at least one standard of care salvage regimen unless the subject refuses such therapy. Multiple myeloma (MM) subjects must have had both a protease inhibitor (PI) and immunomodulatory drugs (IMiD) as part of the last regimen, or at least 3 prior lines of therapy, including a PI and an IMiD. Additionally, subjects must not have disease amenable to definitive locoregional therapy."
                },
                {
                    "inclusion_indicator": true,
                    "display_order": 2,
                    "description": "MAGE-A3/A6 positive tumor as confirmed by the central laboratory"
                },
                {
                    "inclusion_indicator": true,
                    "display_order": 3,
                    "description": "HLA-DPB1*04:01 positive"
                },
                {
                    "inclusion_indicator": true,
                    "display_order": 4,
                    "description": "At least 1 measurable lesion on CT or MRI"
                },
                {
                    "inclusion_indicator": true,
                    "display_order": 5,
                    "description": "No evidence of central nervous system (CNS) disease by MRI or CT of the brain. Note: Prior brain metastasis which have been treated with definitive therapy are eligible provided that the definitive therapy was completed more than six months prior to screening."
                },
                {
                    "inclusion_indicator": true,
                    "display_order": 6,
                    "description": "Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1"
                },
                {
                    "inclusion_indicator": true,
                    "display_order": 7,
                    "description": "Toxicities due to prior therapy must be recovered to baseline or \u2264 grade 1, except for clinically non-significant toxicities such as alopecia"
                },
                {
                    "inclusion_indicator": true,
                    "display_order": 8,
                    "description": "Adequate bone marrow function as evidenced by:"
                },
                {
                    "inclusion_indicator": true,
                    "display_order": 9,
                    "description": "Absolute neutrophil count (ANC) \u2265 1000/mm^3"
                },
                {
                    "inclusion_indicator": true,
                    "display_order": 10,
                    "description": "Platelet \u2265 100/mm^3"
                },
                {
                    "inclusion_indicator": true,
                    "display_order": 11,
                    "description": "Hemoglobin > 8 g/dL"
                },
                {
                    "inclusion_indicator": true,
                    "display_order": 12,
                    "description": "Adequate renal, hepatic, cardiac, and pulmonary function as evidenced by:"
                },
                {
                    "inclusion_indicator": true,
                    "display_order": 13,
                    "description": "Creatinine clearance (as estimated by Cockcroft Gault) \u2265 60 cc/min (24-hour urine creatinine clearance is also acceptable)"
                },
                {
                    "inclusion_indicator": true,
                    "display_order": 14,
                    "description": "Alanine transaminase (ALT)/aspartate aminotransferase (AST) \u2264 2.5 x upper limit normal (ULN) or \u2264 5 x ULN if documented liver metastases"
                },
                {
                    "inclusion_indicator": true,
                    "display_order": 15,
                    "description": "Total bilirubin \u2264 1.5 mg/dL"
                },
                {
                    "inclusion_indicator": true,
                    "display_order": 16,
                    "description": "Cardiac ejection fraction \u2265 50%, no evidence of pericardial effusion as determined by an ECHO, and no clinically significant ECG findings (For ejection fraction only, MUGA scan is also acceptable)"
                },
                {
                    "inclusion_indicator": true,
                    "display_order": 17,
                    "description": "No clinically significant pleural effusion"
                },
                {
                    "inclusion_indicator": true,
                    "display_order": 18,
                    "description": "Baseline oxygen saturation > 92% on room air"
                },
                {
                    "inclusion_indicator": false,
                    "display_order": 19,
                    "description": "Malignancy other than non-melanoma skin cancer, carcinoma in situ, or low grade prostate cancer for which watch-and-wait approach is standard of care, unless disease free for at least 3 years"
                },
                {
                    "inclusion_indicator": false,
                    "display_order": 20,
                    "description": "Clinically significant cardiac disease within last 12 months"
                },
                {
                    "inclusion_indicator": false,
                    "display_order": 21,
                    "description": "Stroke or transient ischemic attack (TIA) within 12 last months"
                },
                {
                    "inclusion_indicator": false,
                    "display_order": 22,
                    "description": "Symptomatic deep vein thrombosis or pulmonary embolism within last 6 months, catheter associated thrombosis is not included as exclusion criteria."
                },
                {
                    "inclusion_indicator": false,
                    "display_order": 23,
                    "description": "Prior T-cell therapy, including KITE-718 or MAGE-A3/A6-targeting therapy."
                },
                {
                    "inclusion_indicator": false,
                    "display_order": 24,
                    "description": "Live vaccine \u2264 4 weeks prior to enrollment"
                },
                {
                    "inclusion_indicator": false,
                    "display_order": 25,
                    "description": "Systemic corticosteroid therapy within 7 days before enrollment."
                },
                {
                    "inclusion_indicator": false,
                    "display_order": 26,
                    "description": "History of severe, immediate hypersensitivity reaction attributed to aminoglycosides"
                },
                {
                    "inclusion_indicator": false,
                    "display_order": 27,
                    "description": "Presence of fungal, bacterial, viral, or other infection requiring IV antimicrobials for management."
                },
                {
                    "inclusion_indicator": false,
                    "display_order": 28,
                    "description": "Presence of any indwelling line or drain. Note: Dedicated central venous access catheters such as a Port-a-Cath or Hickman catheter as well as feeding tubes such as a G-tube, are permitted."
                },
                {
                    "inclusion_indicator": false,
                    "display_order": 29,
                    "description": "Primary immunodeficiency"
                },
                {
                    "inclusion_indicator": false,
                    "display_order": 30,
                    "description": "Autoimmune disease resulting in end-organ injury or requiring systemic immunosuppression/systemic disease modifying agents within the last 2 years prior to enrollment."
                },
                {
                    "inclusion_indicator": false,
                    "display_order": 31,
                    "description": "Known history of infection with HIV, hepatitis B (HBsAg positive), or hepatitis C (anti-HCV positive). A history of treated hepatitis B or hepatitis C is permitted if the viral load is undetectable per quantitative polymerase chain reaction (PCR) and/or nucleic acid testing."
                },
                {
                    "inclusion_indicator": false,
                    "display_order": 32,
                    "description": "Females who are pregnant as confirmed by a positive serum or urine pregnancy test or are breastfeeding."
                },
                {
                    "inclusion_indicator": false,
                    "display_order": 33,
                    "description": "Individuals of both genders of child-bearing potential who are not willing to practice birth control from the time of consent through 6 months after the completion of KITE-718"
                }
            ],
            "structured": {
                "max_age": "999 Years",
                "max_age_number": 999.0,
                "min_age_unit": "Years",
                "max_age_unit": "Years",
                "max_age_in_years": 999.0,
                "gender": "BOTH",
                "accepts_healthy_volunteers": false,
                "min_age": "18 Years",
                "min_age_number": 18.0,
                "min_age_in_years": 18.0
            }
        },
        "completion_date_type_code": "ANTICIPATED",
        "detail_description": "Participants found to be human leukocyte antigen (HLA)-DPB1*04:01 positive and whose tumors\r\n      are MAGE-A3 and/or MAGE-A6 positive can participate if all eligibility criteria are met.\r\n      Other tests required to determine eligibility include a physical exam, electrocardiogram\r\n      (ECG) and echocardiogram (ECHO) of the heart, CT or MRI scans, and blood draws. Eligible\r\n      participants have white blood cells collected by leukapheresis. These cells are genetically\r\n      modified to make the experimental treatment KITE-718. The desired outcome is that the\r\n      genetically modified T cells will target tumor cells that express MAGE-A3 and/or MAGE-A6,\r\n      which are proteins that can be expressed by cancer cells. Participants receive chemotherapy\r\n      prior to the KITE-718 infusion. After the KITE-718 infusion, participants will be followed\r\n      for side effects and have scans performed to see any potential impact on their cancers. Study\r\n      procedures may be performed while hospitalized and/or in the outpatient setting. Subjects who\r\n      received an infusion of KITE-718 will complete the remainder of the 15 year follow-up\r\n      assessments in a separate long-term follow-up study, KT-US-982-5968",
        "official_title": "A Phase 1 Study Evaluating the Safety and Efficacy of MAGE-A3/A6 T Cell Receptor Engineered T Cells (KITE-718) in HLA-DPB1*04:01 Positive Subjects With Advanced Cancers",
        "_phase_sort_order": 4,
        "collaborators": [],
        "associated_studies": [],
        "outcome_measures": [
            {
                "timeframe": "Up to year 2 for solid tumor participants and up to year 5 for multiple myeloma participants",
                "name": "Duration of Response (DOR)",
                "description": "For participants who experience an objective response, DOR is defined as the time from the date of their first objective response to the date of disease progression per modified RECIST v1.1 or consensus panel 1 criteria or death regardless of cause.",
                "type_code": "SECONDARY"
            },
            {
                "timeframe": "Up to 2 years",
                "name": "Levels of MAGE-A3/A6 TCR-transduced T Cells in Blood",
                "description": null,
                "type_code": "SECONDARY"
            },
            {
                "timeframe": "Up to 15 years",
                "name": "Overall Survival",
                "description": "Overall survival is defined as the time from KITE-718 infusion to the date of death.",
                "type_code": "SECONDARY"
            },
            {
                "timeframe": "Up to 15 years",
                "name": "Percentage of Participants Experiencing Adverse Events",
                "description": null,
                "type_code": "SECONDARY"
            },
            {
                "timeframe": "Up to 2 years",
                "name": "Percentage of Participants Experiencing Replication-competent Retrovirus (RCR)",
                "description": null,
                "type_code": "SECONDARY"
            },
            {
                "timeframe": "Up to 2 years",
                "name": "Percentage of Participants with Anti-KITE-718 Antibodies",
                "description": null,
                "type_code": "SECONDARY"
            },
            {
                "timeframe": "Up to 21 days",
                "name": "Phase 1A - Percentage of Participants Experiencing Adverse Events Defined as Dose-Limiting Toxicities",
                "description": "Dose-limiting toxicity is defined as protocol-defined KITE-718 related events with onset within the first 21 days following KITE-718 infusion.",
                "type_code": "PRIMARY"
            },
            {
                "timeframe": "Up to year 2 for solid tumor participants and up to Year 5 for multiple myeloma participants",
                "name": "Phase 1B - Efficacy: Objective Response Rate (ORR)",
                "description": "ORR is defined as complete response + partial response for participants evaluated by RECIST v1.1 and very good partial response (VGPR) or better for multiple myeloma participants evaluated by International Myeloma Working Group (IMWG) Consensus Panel 1 Criteria.",
                "type_code": "PRIMARY"
            },
            {
                "timeframe": "Up to year 2 for solid tumor participants and up to year 5 for multiple myeloma participants",
                "name": "Progression-Free Survival (PFS)",
                "description": "PFS is defined as the time from the KITE-718 infusion date to the date of disease progression per modified RECIST v1.1 or consensus panel 1 criteria or death from any cause.",
                "type_code": "SECONDARY"
            }
        ],
        "phase": "I",
        "central_contact": {
            "phone": null,
            "name": null,
            "type": null,
            "email": null
        },
        "primary_purpose": "TREATMENT",
        "number_of_arms": 1,
        "_study_protocol_type_sort_order": 0,
        "nct_id": "NCT03139370",
        "biomarkers": [
            {
                "eligibility_criterion": "inclusion",
                "inclusion_indicator": "TRIAL",
                "synonyms": [
                    "MAGE-A6 Positive",
                    "MAGE3B Positive",
                    "Melanoma-Associated Antigen 6 Positive"
                ],
                "nci_thesaurus_concept_id": "C135574",
                "name": "MAGEA6 Positive",
                "semantic_types": [
                    "Laboratory or Test Result"
                ],
                "type": [],
                "eligibility_criteria": "inclusion",
                "ancestors": [
                    "C19540",
                    "C3367",
                    "C104517",
                    "C16612",
                    "C177692",
                    "C54306",
                    "C77140",
                    "C35682",
                    "C36292",
                    "C54259"
                ],
                "parents": [
                    "C104517",
                    "C177692"
                ],
                "assay_purpose": "Eligibility Criterion - Inclusion"
            },
            {
                "eligibility_criterion": "inclusion",
                "inclusion_indicator": "TREE",
                "synonyms": [
                    "Diagnostic Test Result",
                    "Test Result"
                ],
                "nci_thesaurus_concept_id": "C77140",
                "name": "Clinical Test Result",
                "semantic_types": [
                    "Finding"
                ],
                "type": [],
                "eligibility_criteria": "inclusion",
                "ancestors": [
                    "C3367"
                ],
                "parents": [
                    "C3367"
                ],
                "assay_purpose": "Eligibility Criterion - Inclusion"
            },
            {
                "eligibility_criterion": "inclusion",
                "inclusion_indicator": "TREE",
                "synonyms": [
                    "MAGEA6",
                    "Melanoma Antigen Family A, 6 Gene"
                ],
                "nci_thesaurus_concept_id": "C104517",
                "name": "MAGEA6 Gene",
                "semantic_types": [
                    "Gene or Genome"
                ],
                "type": [
                    "reference_gene"
                ],
                "eligibility_criteria": "inclusion",
                "ancestors": [
                    "C54306",
                    "C19540",
                    "C54259",
                    "C16612"
                ],
                "parents": [
                    "C54306"
                ],
                "assay_purpose": "Eligibility Criterion - Inclusion"
            },
            {
                "eligibility_criterion": "inclusion",
                "inclusion_indicator": "TRIAL",
                "synonyms": [
                    "HLA-DPB1*0401 Positive",
                    "HLA-DPB1*04:01 Positive",
                    "HLA-DPB1*04:01 Positive Cells Present"
                ],
                "nci_thesaurus_concept_id": "C146725",
                "name": "HLA-DPB1*0401 Positive Cells Present",
                "semantic_types": [
                    "Laboratory or Test Result"
                ],
                "type": [],
                "eligibility_criteria": "inclusion",
                "ancestors": [
                    "C16616",
                    "C16612",
                    "C69179",
                    "C3367",
                    "C177692",
                    "C25790",
                    "C77140",
                    "C36292",
                    "C35682",
                    "C29953",
                    "C16812"
                ],
                "parents": [
                    "C29953",
                    "C69179"
                ],
                "assay_purpose": "Eligibility Criterion - Inclusion"
            },
            {
                "eligibility_criterion": "inclusion",
                "inclusion_indicator": "TREE",
                "synonyms": [],
                "nci_thesaurus_concept_id": "C69179",
                "name": "HLA-DPB1*04 Positive Cells Present",
                "semantic_types": [
                    "Laboratory or Test Result"
                ],
                "type": [],
                "eligibility_criteria": "inclusion",
                "ancestors": [
                    "C16616",
                    "C16612",
                    "C3367",
                    "C177692",
                    "C25790",
                    "C77140",
                    "C36292",
                    "C35682",
                    "C29953",
                    "C16812"
                ],
                "parents": [
                    "C177692",
                    "C29953"
                ],
                "assay_purpose": "Eligibility Criterion - Inclusion"
            },
            {
                "eligibility_criterion": "inclusion",
                "inclusion_indicator": "TREE",
                "synonyms": [
                    "Cancer-Promoting Gene"
                ],
                "nci_thesaurus_concept_id": "C19540",
                "name": "Cancer Gene",
                "semantic_types": [
                    "Gene or Genome"
                ],
                "type": [],
                "eligibility_criteria": "inclusion",
                "ancestors": [
                    "C16612"
                ],
                "parents": [
                    "C16612"
                ],
                "assay_purpose": "Eligibility Criterion - Inclusion"
            },
            {
                "eligibility_criterion": "inclusion",
                "inclusion_indicator": "TREE",
                "synonyms": [],
                "nci_thesaurus_concept_id": "C25790",
                "name": "Immunoprotein Gene",
                "semantic_types": [
                    "Gene or Genome"
                ],
                "type": [],
                "eligibility_criteria": "inclusion",
                "ancestors": [
                    "C16612"
                ],
                "parents": [
                    "C16612"
                ],
                "assay_purpose": "Eligibility Criterion - Inclusion"
            },
            {
                "eligibility_criterion": "inclusion",
                "inclusion_indicator": "TREE",
                "synonyms": [
                    "LAB_RESULT",
                    "Lab Findings",
                    "Laboratory Finding",
                    "Laboratory Report",
                    "Labs",
                    "Test Result",
                    "test_result"
                ],
                "nci_thesaurus_concept_id": "C36292",
                "name": "Laboratory Test Result",
                "semantic_types": [
                    "Laboratory or Test Result"
                ],
                "type": [],
                "eligibility_criteria": "inclusion",
                "ancestors": [
                    "C3367",
                    "C77140"
                ],
                "parents": [
                    "C77140"
                ],
                "assay_purpose": "Eligibility Criterion - Inclusion"
            },
            {
                "eligibility_criterion": "inclusion",
                "inclusion_indicator": "TREE",
                "synonyms": [
                    "MAGEA3",
                    "Melanoma Antigen, Family A, 3 Gene"
                ],
                "nci_thesaurus_concept_id": "C17951",
                "name": "MAGEA3 Gene",
                "semantic_types": [
                    "Gene or Genome"
                ],
                "type": [
                    "reference_gene"
                ],
                "eligibility_criteria": "inclusion",
                "ancestors": [
                    "C54259",
                    "C19540",
                    "C54306",
                    "C16612"
                ],
                "parents": [
                    "C54306"
                ],
                "assay_purpose": "Eligibility Criterion - Inclusion"
            },
            {
                "eligibility_criterion": "inclusion",
                "inclusion_indicator": "TREE",
                "synonyms": [
                    "HLA Complex Gene"
                ],
                "nci_thesaurus_concept_id": "C16812",
                "name": "Major Histocompatibility Complex Gene",
                "semantic_types": [
                    "Gene or Genome"
                ],
                "type": [],
                "eligibility_criteria": "inclusion",
                "ancestors": [
                    "C16612",
                    "C25790"
                ],
                "parents": [
                    "C25790"
                ],
                "assay_purpose": "Eligibility Criterion - Inclusion"
            },
            {
                "eligibility_criterion": "inclusion",
                "inclusion_indicator": "TREE",
                "synonyms": [
                    "Expressed",
                    "Expression Detected"
                ],
                "nci_thesaurus_concept_id": "C177692",
                "name": "Expression Positive",
                "semantic_types": [
                    "Laboratory or Test Result"
                ],
                "type": [],
                "eligibility_criteria": "inclusion",
                "ancestors": [
                    "C3367",
                    "C36292",
                    "C35682",
                    "C77140"
                ],
                "parents": [
                    "C35682"
                ],
                "assay_purpose": "Eligibility Criterion - Inclusion"
            },
            {
                "eligibility_criterion": "inclusion",
                "inclusion_indicator": "TREE",
                "synonyms": [
                    "Genes"
                ],
                "nci_thesaurus_concept_id": "C16612",
                "name": "Gene",
                "semantic_types": [
                    "Gene or Genome"
                ],
                "type": [
                    "branch"
                ],
                "eligibility_criteria": "inclusion",
                "ancestors": [],
                "parents": [],
                "assay_purpose": "Eligibility Criterion - Inclusion"
            },
            {
                "eligibility_criterion": "inclusion",
                "inclusion_indicator": "TREE",
                "synonyms": [],
                "nci_thesaurus_concept_id": "C54306",
                "name": "Tumor Antigen Gene",
                "semantic_types": [
                    "Gene or Genome"
                ],
                "type": [],
                "eligibility_criteria": "inclusion",
                "ancestors": [
                    "C54259",
                    "C16612",
                    "C19540"
                ],
                "parents": [
                    "C19540",
                    "C54259"
                ],
                "assay_purpose": "Eligibility Criterion - Inclusion"
            },
            {
                "eligibility_criterion": "inclusion",
                "inclusion_indicator": "TREE",
                "synonyms": [
                    "Observable Entity"
                ],
                "nci_thesaurus_concept_id": "C3367",
                "name": "Finding",
                "semantic_types": [
                    "Finding"
                ],
                "type": [
                    "branch"
                ],
                "eligibility_criteria": "inclusion",
                "ancestors": [],
                "parents": [],
                "assay_purpose": "Eligibility Criterion - Inclusion"
            },
            {
                "eligibility_criterion": "inclusion",
                "inclusion_indicator": "TREE",
                "synonyms": [
                    "Class II MHC",
                    "MHC Class II"
                ],
                "nci_thesaurus_concept_id": "C16616",
                "name": "MHC Class II Gene",
                "semantic_types": [
                    "Gene or Genome"
                ],
                "type": [],
                "eligibility_criteria": "inclusion",
                "ancestors": [
                    "C16612",
                    "C16812",
                    "C25790"
                ],
                "parents": [
                    "C16812"
                ],
                "assay_purpose": "Eligibility Criterion - Inclusion"
            },
            {
                "eligibility_criterion": "inclusion",
                "inclusion_indicator": "TREE",
                "synonyms": [
                    "HLA-DPB1",
                    "Major Histocompatibility Complex, Class II, DP Beta 1 Gene"
                ],
                "nci_thesaurus_concept_id": "C29953",
                "name": "HLA-DPB1 Gene",
                "semantic_types": [
                    "Gene or Genome"
                ],
                "type": [
                    "reference_gene"
                ],
                "eligibility_criteria": "inclusion",
                "ancestors": [
                    "C25790",
                    "C16612",
                    "C16812",
                    "C16616"
                ],
                "parents": [
                    "C16616"
                ],
                "assay_purpose": "Eligibility Criterion - Inclusion"
            },
            {
                "eligibility_criterion": "inclusion",
                "inclusion_indicator": "TREE",
                "synonyms": [
                    "Positive",
                    "positive test result"
                ],
                "nci_thesaurus_concept_id": "C35682",
                "name": "Positive Laboratory Test Result",
                "semantic_types": [
                    "Laboratory or Test Result"
                ],
                "type": [],
                "eligibility_criteria": "inclusion",
                "ancestors": [
                    "C3367",
                    "C36292",
                    "C77140"
                ],
                "parents": [
                    "C36292"
                ],
                "assay_purpose": "Eligibility Criterion - Inclusion"
            },
            {
                "eligibility_criterion": "inclusion",
                "inclusion_indicator": "TREE",
                "synonyms": [
                    "Antigen-encoding Gene"
                ],
                "nci_thesaurus_concept_id": "C54259",
                "name": "Antigen Gene",
                "semantic_types": [
                    "Gene or Genome"
                ],
                "type": [],
                "eligibility_criteria": "inclusion",
                "ancestors": [
                    "C16612"
                ],
                "parents": [
                    "C16612"
                ],
                "assay_purpose": "Eligibility Criterion - Inclusion"
            },
            {
                "eligibility_criterion": "inclusion",
                "inclusion_indicator": "TRIAL",
                "synonyms": [
                    "HIP8 Positive",
                    "HYPD Positive",
                    "MAGE-3 Positive",
                    "MAGE-A3 Positive",
                    "MAGE3 Positive",
                    "Melanoma-Associated Antigen 3 Positive"
                ],
                "nci_thesaurus_concept_id": "C135575",
                "name": "MAGEA3 Positive",
                "semantic_types": [
                    "Laboratory or Test Result"
                ],
                "type": [],
                "eligibility_criteria": "inclusion",
                "ancestors": [
                    "C36292",
                    "C16612",
                    "C54306",
                    "C17951",
                    "C35682",
                    "C77140",
                    "C19540",
                    "C54259",
                    "C3367",
                    "C177692"
                ],
                "parents": [
                    "C177692",
                    "C17951"
                ],
                "assay_purpose": "Eligibility Criterion - Inclusion"
            }
        ],
        "classification_code": null,
        "current_trial_status_date": "2021-09-29",
        "diseases": [
            {
                "inclusion_indicator": "TRIAL",
                "is_lead_disease": false,
                "synonyms": [
                    "Recurrent Malignant Solid Neoplasm",
                    "Recurrent Solid Neoplasm",
                    "Relapsed Solid Tumor",
                    "Recurrent Solid Tumor",
                    "Relapsed Malignant Solid Neoplasm",
                    "Relapsed Solid Neoplasm"
                ],
                "nci_thesaurus_concept_id": "C127153",
                "name": "Recurrent Malignant Solid Tumor",
                "type": [
                    "stage"
                ],
                "parents": [
                    "C132146",
                    "C4813"
                ]
            },
            {
                "inclusion_indicator": "TRIAL",
                "is_lead_disease": true,
                "synonyms": [
                    "Advanced Malignant Solid Neoplasm",
                    "Advanced Non-Hematologic Malignancy",
                    "Advanced Solid Neoplasm",
                    "Advanced Solid Tumor"
                ],
                "nci_thesaurus_concept_id": "C129707",
                "name": "Advanced Malignant Solid Tumor",
                "type": [
                    "subtype"
                ],
                "parents": [
                    "C127155",
                    "C9270"
                ]
            },
            {
                "inclusion_indicator": "TRIAL",
                "is_lead_disease": false,
                "synonyms": [
                    "Refractory Malignant Solid Neoplasm"
                ],
                "nci_thesaurus_concept_id": "C133737",
                "name": "Refractory Malignant Solid Tumor",
                "type": [
                    "subtype"
                ],
                "parents": [
                    "C120186",
                    "C132146"
                ]
            },
            {
                "inclusion_indicator": "TREE",
                "is_lead_disease": true,
                "synonyms": [
                    "Metastatic Cancer"
                ],
                "nci_thesaurus_concept_id": "C36263",
                "name": "Metastatic Malignant Neoplasm",
                "type": [
                    "subtype"
                ],
                "parents": [
                    "C4968",
                    "C3261"
                ]
            },
            {
                "inclusion_indicator": "TREE",
                "is_lead_disease": true,
                "synonyms": [
                    "Neoplasms, NOS",
                    "Neoplasia",
                    "Tumor, NOS",
                    "Neoplastic Growth",
                    "Neoplasm",
                    "Neoplastic Disease",
                    "tumor",
                    "Neoplasm, NOS"
                ],
                "nci_thesaurus_concept_id": "C3262",
                "name": "Other Neoplasm",
                "type": [
                    "maintype"
                ],
                "parents": [
                    "C2991"
                ]
            },
            {
                "inclusion_indicator": "TREE",
                "is_lead_disease": true,
                "synonyms": [
                    "Advanced Cancer"
                ],
                "nci_thesaurus_concept_id": "C9270",
                "name": "Advanced Malignant Neoplasm",
                "type": [
                    "subtype"
                ],
                "parents": [
                    "C36263"
                ]
            },
            {
                "inclusion_indicator": "TREE",
                "is_lead_disease": true,
                "synonyms": [
                    "Solid Tumour",
                    "Solid tumor, NOS",
                    "Solid Neoplasm"
                ],
                "nci_thesaurus_concept_id": "C9292",
                "name": "Solid Tumor",
                "type": [
                    "maintype"
                ],
                "parents": [
                    "C7062"
                ]
            },
            {
                "inclusion_indicator": "TREE",
                "is_lead_disease": true,
                "synonyms": [
                    "Metastatic Tumor",
                    "Tumor, metastatic",
                    "Neoplasm, metastatic"
                ],
                "nci_thesaurus_concept_id": "C3261",
                "name": "Metastatic Neoplasm",
                "type": [
                    "subtype"
                ],
                "parents": [
                    "C7062"
                ]
            },
            {
                "inclusion_indicator": "TREE",
                "is_lead_disease": true,
                "synonyms": [
                    "Metastatic Solid Neoplasm",
                    "Metastatic Solid Tumor",
                    "Metastatic Tumor",
                    "Metastatic Malignant Solid Neoplasm"
                ],
                "nci_thesaurus_concept_id": "C127155",
                "name": "Metastatic Malignant Solid Tumor",
                "type": [
                    "subtype"
                ],
                "parents": [
                    "C36263",
                    "C132146"
                ]
            },
            {
                "inclusion_indicator": "TREE",
                "is_lead_disease": true,
                "synonyms": [
                    "Neoplasm, secondary",
                    "Secondary Tumor",
                    "Tumor, secondary"
                ],
                "nci_thesaurus_concept_id": "C36255",
                "name": "Secondary Neoplasm",
                "type": [
                    "subtype"
                ],
                "parents": [
                    "C7062"
                ]
            },
            {
                "inclusion_indicator": "TREE",
                "is_lead_disease": true,
                "synonyms": [
                    "Neoplasm, malignant",
                    "Cancer",
                    "Malignant Growth",
                    "Tumor, malignant, NOS",
                    "Malignant Tumor",
                    "Malignancy",
                    "CA",
                    "Unclassified tumor, malignant",
                    "Malignant Neoplastic Disease"
                ],
                "nci_thesaurus_concept_id": "C9305",
                "name": "Malignant Neoplasm",
                "type": [
                    "subtype"
                ],
                "parents": [
                    "C7062"
                ]
            },
            {
                "inclusion_indicator": "TREE",
                "is_lead_disease": true,
                "synonyms": [],
                "nci_thesaurus_concept_id": "C7062",
                "name": "Neoplasm by Special Category",
                "type": [
                    "subtype"
                ],
                "parents": [
                    "C3262"
                ]
            },
            {
                "inclusion_indicator": "TREE",
                "is_lead_disease": true,
                "synonyms": [
                    "Secondary Malignancy",
                    "Secondary Cancer"
                ],
                "nci_thesaurus_concept_id": "C4968",
                "name": "Secondary Malignant Neoplasm",
                "type": [
                    "subtype"
                ],
                "parents": [
                    "C9305",
                    "C36255"
                ]
            },
            {
                "inclusion_indicator": "TREE",
                "is_lead_disease": true,
                "synonyms": [
                    "disease term",
                    "Disease",
                    "Diseases and Disorders",
                    "disease type",
                    "Disease or Disorder",
                    "Diagnosis",
                    "disease_term",
                    "condition",
                    "disease_type",
                    "Diseases",
                    "Disease or Disorder, Non-Neoplastic",
                    "Disorders",
                    "Disorder"
                ],
                "nci_thesaurus_concept_id": "C2991",
                "name": "Other Disease",
                "type": [
                    "maintype"
                ],
                "parents": []
            },
            {
                "inclusion_indicator": "TREE",
                "is_lead_disease": true,
                "synonyms": [
                    "Malignant Solid Neoplasm"
                ],
                "nci_thesaurus_concept_id": "C132146",
                "name": "Malignant Solid Tumor",
                "type": [
                    "subtype"
                ],
                "parents": [
                    "C9292",
                    "C9305"
                ]
            },
            {
                "inclusion_indicator": "TREE",
                "is_lead_disease": false,
                "synonyms": [
                    "Refractory Tumor"
                ],
                "nci_thesaurus_concept_id": "C7628",
                "name": "Refractory Neoplasm",
                "type": [
                    "subtype"
                ],
                "parents": [
                    "C7062"
                ]
            },
            {
                "inclusion_indicator": "TREE",
                "is_lead_disease": false,
                "synonyms": [
                    "Recurrence",
                    "Recurrent",
                    "Recurrent Tumor",
                    "Neoplasm Recurrence"
                ],
                "nci_thesaurus_concept_id": "C4798",
                "name": "Recurrent Neoplasm",
                "type": [
                    "stage"
                ],
                "parents": [
                    "C7062"
                ]
            },
            {
                "inclusion_indicator": "TREE",
                "is_lead_disease": false,
                "synonyms": [
                    "Recurrence",
                    "Recurrent Cancer",
                    "Recurrent Malignant Tumor"
                ],
                "nci_thesaurus_concept_id": "C4813",
                "name": "Recurrent Malignant Neoplasm",
                "type": [
                    "stage"
                ],
                "parents": [
                    "C9305",
                    "C4798"
                ]
            },
            {
                "inclusion_indicator": "TREE",
                "is_lead_disease": false,
                "synonyms": [
                    "resistant cancer",
                    "Refractory Cancer",
                    "clinical resistance"
                ],
                "nci_thesaurus_concept_id": "C120186",
                "name": "Refractory Malignant Neoplasm",
                "type": [
                    "subtype"
                ],
                "parents": [
                    "C9305",
                    "C7628"
                ]
            }
        ],
        "_primary_purpose_sort_order": 0,
        "protocol_id": "KITE-718-301",
        "active_sites_count": 5,
        "lead_org_cancer_center": null,
        "arms": [
            {
                "interventions": [
                    {
                        "inclusion_indicator": "TREE",
                        "synonyms": [
                            "Antineoplastic Biological",
                            "Anti-cancer Biological Agent",
                            "Antineoplastic Biotherapeutic",
                            "Anticancer Biological"
                        ],
                        "nci_thesaurus_concept_id": "C129821",
                        "name": "Antineoplastic Biological Agent",
                        "description": null,
                        "type": "Biological/Vaccine",
                        "category": "agent category",
                        "parents": [
                            "C274",
                            "C307"
                        ]
                    },
                    {
                        "inclusion_indicator": "TREE",
                        "synonyms": [
                            "Autologous T-cells"
                        ],
                        "nci_thesaurus_concept_id": "C28681",
                        "name": "Therapeutic Autologous Lymphocytes",
                        "description": null,
                        "type": "Biological/Vaccine",
                        "category": "agent category",
                        "parents": [
                            "C142078"
                        ]
                    },
                    {
                        "inclusion_indicator": "TREE",
                        "synonyms": [],
                        "nci_thesaurus_concept_id": "C2150",
                        "name": "Ribonucleotide Reductase Inhibitor",
                        "description": null,
                        "type": "Drug",
                        "category": "agent category",
                        "parents": [
                            "C471"
                        ]
                    },
                    {
                        "inclusion_indicator": "TREE",
                        "synonyms": [
                            "Chemotherapy Alkylating Agents",
                            "Chemotherapy Alkylators"
                        ],
                        "nci_thesaurus_concept_id": "C1590",
                        "name": "Antineoplastic Alkylating Agent",
                        "description": null,
                        "type": "Drug",
                        "category": "agent category",
                        "parents": [
                            "C2842"
                        ]
                    },
                    {
                        "inclusion_indicator": "TREE",
                        "synonyms": [
                            "ACT Agent",
                            "Adoptive Cell Therapy Agent",
                            "Adoptive Cellular Therapy Agent",
                            "Adoptive Cell-based Agent",
                            "Adoptive Cell Transfer Agent"
                        ],
                        "nci_thesaurus_concept_id": "C142078",
                        "name": "Adoptive Immunotherapy",
                        "description": null,
                        "type": "Biological/Vaccine",
                        "category": "agent category",
                        "parents": [
                            "C307",
                            "C308"
                        ]
                    },
                    {
                        "inclusion_indicator": "TREE",
                        "synonyms": [],
                        "nci_thesaurus_concept_id": "C2842",
                        "name": "DNA Binding Agent",
                        "description": null,
                        "type": "Drug",
                        "category": "agent category",
                        "parents": [
                            "C274"
                        ]
                    },
                    {
                        "inclusion_indicator": "TREE",
                        "synonyms": [
                            "Gene Therapy Agent"
                        ],
                        "nci_thesaurus_concept_id": "C1962",
                        "name": "Gene Therapy",
                        "description": null,
                        "type": "Biological/Vaccine",
                        "category": "agent category",
                        "parents": [
                            "C307"
                        ]
                    },
                    {
                        "inclusion_indicator": "TREE",
                        "synonyms": [
                            "TCR T Cells",
                            "TCR T-cells",
                            "TCR-engineered T-cells",
                            "TCR-modified T Cells",
                            "T-cell Receptor-engineered T-lymphocytes",
                            "T-cell Receptor-engineered T Cells"
                        ],
                        "nci_thesaurus_concept_id": "C138180",
                        "name": "T-cell Receptor-engineered T-cells",
                        "description": null,
                        "type": "Biological/Vaccine",
                        "category": "agent category",
                        "parents": [
                            "C154231"
                        ]
                    },
                    {
                        "inclusion_indicator": "TREE",
                        "synonyms": [
                            "Immunosuppressive Agents"
                        ],
                        "nci_thesaurus_concept_id": "C574",
                        "name": "Immunosuppressant",
                        "description": null,
                        "type": "Drug",
                        "category": "agent category",
                        "parents": [
                            "C308"
                        ]
                    },
                    {
                        "inclusion_indicator": "TREE",
                        "synonyms": [
                            "Anti-cancer Immune Cell",
                            "Antineoplastic Immune Cells"
                        ],
                        "nci_thesaurus_concept_id": "C129826",
                        "name": "Antineoplastic Immune Cell",
                        "description": null,
                        "type": "Biological/Vaccine",
                        "category": "agent category",
                        "parents": [
                            "C129821",
                            "C142078",
                            "C129820"
                        ]
                    },
                    {
                        "inclusion_indicator": "TREE",
                        "synonyms": [
                            "Biomodulators",
                            "BRM",
                            "Biological Response Modifier",
                            "Immunomodulators",
                            "Immune Regulators",
                            "Immune Mediators",
                            "Immunomodulating Agent",
                            "Immunopotentiators",
                            "Immune Modulators",
                            "Immunotherapeutic Agent",
                            "Immunotherapy Agent",
                            "Immunomodulatory Agent"
                        ],
                        "nci_thesaurus_concept_id": "C308",
                        "name": "Immunotherapy",
                        "description": null,
                        "type": "Drug",
                        "category": "agent category",
                        "parents": [
                            "C1909"
                        ]
                    },
                    {
                        "inclusion_indicator": "TRIAL",
                        "synonyms": [],
                        "nci_thesaurus_concept_id": "C1094",
                        "name": "Fludarabine",
                        "description": null,
                        "type": "Drug",
                        "category": "agent",
                        "parents": [
                            "C2150",
                            "C1556"
                        ]
                    },
                    {
                        "inclusion_indicator": "TRIAL",
                        "synonyms": [],
                        "nci_thesaurus_concept_id": "C135534",
                        "name": "Autologous MAGE-A3/A6-specific TCR Gene-engineered Lymphocytes KITE-718",
                        "description": null,
                        "type": "Biological/Vaccine",
                        "category": "agent",
                        "parents": [
                            "C129826",
                            "C28681",
                            "C138180"
                        ]
                    },
                    {
                        "inclusion_indicator": "TREE",
                        "synonyms": [
                            "Antineoplastic Biological Response Modifier",
                            "Antineoplastic BRM",
                            "Anti-cancer Immunotherapeutic",
                            "Antineoplastic Immunotherapeutic"
                        ],
                        "nci_thesaurus_concept_id": "C129820",
                        "name": "Antineoplastic Immunomodulating Agent",
                        "description": null,
                        "type": "Biological/Vaccine",
                        "category": "agent category",
                        "parents": [
                            "C274",
                            "C308"
                        ]
                    },
                    {
                        "inclusion_indicator": "TREE",
                        "synonyms": [
                            "Enzyme Inhibitor Agent",
                            "Enzyme Antagonist",
                            "Enzyme Inhibitor Drug"
                        ],
                        "nci_thesaurus_concept_id": "C471",
                        "name": "Enzyme Inhibitor",
                        "description": null,
                        "type": "Drug",
                        "category": "agent category",
                        "parents": [
                            "C1909"
                        ]
                    },
                    {
                        "inclusion_indicator": "TREE",
                        "synonyms": [
                            "Biopharmaceuticals",
                            "Biologicals",
                            "Biologics",
                            "Biological Products",
                            "Immunologics",
                            "Immunologic, Immunochemical"
                        ],
                        "nci_thesaurus_concept_id": "C307",
                        "name": "Biological Agent",
                        "description": null,
                        "type": "Biological/Vaccine",
                        "category": "agent category",
                        "parents": [
                            "C1909"
                        ]
                    },
                    {
                        "inclusion_indicator": "TREE",
                        "synonyms": [],
                        "nci_thesaurus_concept_id": "C2114",
                        "name": "Mustard Agent",
                        "description": null,
                        "type": "Drug",
                        "category": "agent category",
                        "parents": [
                            "C1590"
                        ]
                    },
                    {
                        "inclusion_indicator": "TREE",
                        "synonyms": [
                            "Pharmaceutical Agent",
                            "Drug",
                            "Drug Substance",
                            "Pharmacological Substance",
                            "Pharmaceuticals",
                            "Agent",
                            "Pharmacologic Agent"
                        ],
                        "nci_thesaurus_concept_id": "C1909",
                        "name": "Pharmacologic Substance",
                        "description": null,
                        "type": "Biological/Vaccine",
                        "category": "agent category",
                        "parents": [
                            "C1908"
                        ]
                    },
                    {
                        "inclusion_indicator": "TREE",
                        "synonyms": [
                            "Purine Inhibitors"
                        ],
                        "nci_thesaurus_concept_id": "C1556",
                        "name": "Purine Antagonist",
                        "description": null,
                        "type": "Drug",
                        "category": "agent category",
                        "parents": [
                            "C272"
                        ]
                    },
                    {
                        "inclusion_indicator": "TREE",
                        "synonyms": [
                            "Cell-based Gene Therapy Agent",
                            "Genetically-altered Immune Cell",
                            "Genetically-modified Immune Cell"
                        ],
                        "nci_thesaurus_concept_id": "C154231",
                        "name": "Genetically-engineered Immune Cell",
                        "description": null,
                        "type": "Biological/Vaccine",
                        "category": "agent category",
                        "parents": [
                            "C1962",
                            "C142078"
                        ]
                    },
                    {
                        "inclusion_indicator": "TREE",
                        "synonyms": [
                            "Chemotherapeutic Agents, Neoplastic Disease",
                            "Cancer Drug",
                            "Tumor-Specific Treatment Agents",
                            "Antiproliferative Agents",
                            "Anti-Tumor Drugs",
                            "Antiproliferative Drugs",
                            "Antineoplastic Drugs",
                            "Antineoplastics",
                            "Anti-Tumor Agents",
                            "Anti-Cancer Agents"
                        ],
                        "nci_thesaurus_concept_id": "C274",
                        "name": "Antineoplastic Agent",
                        "description": null,
                        "type": "Biological/Vaccine",
                        "category": "agent category",
                        "parents": [
                            "C1909"
                        ]
                    },
                    {
                        "inclusion_indicator": "TREE",
                        "synonyms": [
                            "Chemotherapeutic Agents, Neoplastic Disease",
                            "Cancer Drug",
                            "Tumor-Specific Treatment Agents",
                            "Antiproliferative Agents",
                            "Anti-Tumor Drugs",
                            "Antiproliferative Drugs",
                            "Antineoplastic Drugs",
                            "Antineoplastics",
                            "Anti-Tumor Agents",
                            "Anti-Cancer Agents"
                        ],
                        "nci_thesaurus_concept_id": "C274",
                        "name": "Antineoplastic Agent",
                        "description": null,
                        "type": "Drug",
                        "category": "agent category",
                        "parents": [
                            "C1909"
                        ]
                    },
                    {
                        "inclusion_indicator": "TREE",
                        "synonyms": [],
                        "nci_thesaurus_concept_id": "C1908",
                        "name": "Drug, Food, Chemical or Biomedical Material",
                        "description": null,
                        "type": "Drug",
                        "category": "agent category",
                        "parents": []
                    },
                    {
                        "inclusion_indicator": "TREE",
                        "synonyms": [
                            "Biomodulators",
                            "BRM",
                            "Biological Response Modifier",
                            "Immunomodulators",
                            "Immune Regulators",
                            "Immune Mediators",
                            "Immunomodulating Agent",
                            "Immunopotentiators",
                            "Immune Modulators",
                            "Immunotherapeutic Agent",
                            "Immunotherapy Agent",
                            "Immunomodulatory Agent"
                        ],
                        "nci_thesaurus_concept_id": "C308",
                        "name": "Immunotherapy",
                        "description": null,
                        "type": "Biological/Vaccine",
                        "category": "agent category",
                        "parents": [
                            "C1909"
                        ]
                    },
                    {
                        "inclusion_indicator": "TREE",
                        "synonyms": [
                            "Antimetabolites"
                        ],
                        "nci_thesaurus_concept_id": "C272",
                        "name": "Antimetabolite",
                        "description": null,
                        "type": "Drug",
                        "category": "agent category",
                        "parents": [
                            "C274"
                        ]
                    },
                    {
                        "inclusion_indicator": "TRIAL",
                        "synonyms": [
                            "Fosfaseron",
                            "Cytophosphan",
                            "Cycloblastin",
                            "Cicloxal",
                            "Cyclostin",
                            "Genuxal",
                            "Genoxal",
                            "Cycloblastine",
                            "Carloxan",
                            "Ledoxina",
                            "Cyclostine",
                            "CYCLO-cell"
                        ],
                        "nci_thesaurus_concept_id": "C405",
                        "name": "Cyclophosphamide",
                        "description": "A synthetic alkylating agent chemically related to the nitrogen mustards with antineoplastic and immunosuppressive activities.  In the liver, cyclophosphamide is converted to the active metabolites aldophosphamide and phosphoramide mustard, which bind to DNA, thereby inhibiting DNA replication and initiating cell death. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)Health professional",
                        "type": "Drug",
                        "category": "agent",
                        "parents": [
                            "C574",
                            "C697"
                        ]
                    },
                    {
                        "inclusion_indicator": "TREE",
                        "synonyms": [],
                        "nci_thesaurus_concept_id": "C1908",
                        "name": "Drug, Food, Chemical or Biomedical Material",
                        "description": null,
                        "type": "Biological/Vaccine",
                        "category": "agent category",
                        "parents": []
                    },
                    {
                        "inclusion_indicator": "TREE",
                        "synonyms": [],
                        "nci_thesaurus_concept_id": "C697",
                        "name": "Nitrogen Mustard Compound",
                        "description": null,
                        "type": "Drug",
                        "category": "agent category",
                        "parents": [
                            "C2114"
                        ]
                    },
                    {
                        "inclusion_indicator": "TREE",
                        "synonyms": [
                            "Pharmaceutical Agent",
                            "Drug",
                            "Drug Substance",
                            "Pharmacological Substance",
                            "Pharmaceuticals",
                            "Agent",
                            "Pharmacologic Agent"
                        ],
                        "nci_thesaurus_concept_id": "C1909",
                        "name": "Pharmacologic Substance",
                        "description": null,
                        "type": "Drug",
                        "category": "agent category",
                        "parents": [
                            "C1908"
                        ]
                    }
                ],
                "name": "Arm not specified",
                "description": null,
                "type": null
            },
            {
                "interventions": [],
                "name": "KITE-718",
                "description": "Phase 1A: Participants will receive cyclophosphamide and fludarabine conditioning chemotherapy followed by the investigational treatment, KITE-718.\r\nPhase 1 B: Participants will receive cyclophosphamide and fludarabine conditioning chemotherapy followed by the investigational treatment, KITE-718, at a dose selected based on Phase 1A.",
                "type": "EXPERIMENTAL"
            }
        ],
        "study_model_code": null,
        "nci_id": "NCI-2017-00835",
        "why_study_stopped": null,
        "brief_summary": "The primary objectives of Phase 1A are to evaluate the safety of KITE-718, determine a\r\n      recommended Phase 1B dose, and to evaluate the efficacy of KITE-718 in Phase 1B.",
        "brief_title": "Safety and Efficacy of MAGE-A3/A6 T Cell Receptor Engineered T Cells (KITE-718) in HLA-DPB1*04:01 Positive Adults With Advanced Cancers",
        "status_history": [
            {
                "status_date": "2021-09-29T00:00:00.000001",
                "status": "CLOSED_TO_ACCRUAL"
            },
            {
                "status_date": "2017-05-03T14:14:03.442",
                "status": "ACTIVE"
            }
        ],
        "study_population_description": null,
        "sampling_method_code": null,
        "minimum_target_accrual_number": 75,
        "_current_trial_status_sort_order": 7,
        "start_date": "2017-05-08",
        "record_verification_date": "2022-01-01",
        "ctep_id": null,
        "current_trial_status": "Closed to Accrual",
        "study_model_other_text": null,
        "masking": {
            "role_caregiver": null,
            "masking": null,
            "role_investigator": null,
            "role_outcome_assessor": null,
            "role_subject": null,
            "allocation_code": "NA"
        },
        "acronym": null,
        "nci_funded": "Indirect",
        "anatomic_sites": [
            "Multiple"
        ],
        "ccr_id": null,
        "start_date_type_code": "ACTUAL",
        "principal_investigator": null,
        "study_source": "Industrial",
        "completion_date": "2022-03-01",
        "study_subtype_code": null,
        "study_protocol_type": "Interventional"
    }
]